预约演示
更新于：2024-12-31
Parecoxib Sodium
帕瑞昔布钠
更新于：2024-12-31
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2002-03-22), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H18N2NaO4S |
InChIKeyIMBMHWVEMVJSIQ-UHFFFAOYSA-N |
CAS号198470-85-8 |
关联
109
项与 帕瑞昔布钠 相关的临床试验NCT06579274
A Randomized, Placebo-controlled, Double-blind Clinical Trial Evaluating the Safety and Efficacy of Parecoxib in Hospitalized Patients With Spontaneous Subarachnoid Hemorrhage
NCT06721988
Exploring the Effect of Preventive Analgesia with Oxycodone and Parecoxib Sodium on the Chronification of Acute Pain in Adult Patients Underwent Laparoscopic-assisted Abdominal Major Surgery
NCT06600282
A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of Parecoxib After Intravenous Bolus of Parecoxib in Healthy Volunteers Under Fasting Conditions
100 项与 帕瑞昔布钠 相关的临床结果
登录后查看更多信息
100 项与 帕瑞昔布钠 相关的转化医学
登录后查看更多信息
100 项与 帕瑞昔布钠 相关的专利（医药）
登录后查看更多信息
657
项与 帕瑞昔布钠 相关的文献（医药）2024-12-31International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy
Article
作者: Cheng, Chih-Chung ; Yeh, Hung-Chieh ; Chang, Sheng-Chi ; Ho, Chien-Lin ; Su, Pei-Wen
PURPOSE:
Cisplatin is commonly prescribed in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy. Acute kidney injury (AKI) is regarded as a common complication after HIPEC combined with cytoreductive surgery (CRS). However, post-HIPEC chronic kidney disease (CKD) is scarce and less investigated. This study aims to investigate the incidence of CKD following cisplatin-based HIPEC and to analyse the associated risk factors.
MATERIALS AND METHODS:
From January 2016 to August 2021, a total of 55 patients treated with CRS and cisplatin-based HIPEC for peritoneal carcinomatosis were categorized retrospectively into groups, with and without CKD. Demographics, comorbidity, surgery, postoperative management, and complications were collected to evaluate risk factors for cisplatin-based HIPEC-related CKD. Univariate and multivariate analyses were conducted to confirm the correlation between different variables and CKD occurrence.
RESULTS:
Of the 55 patients, 24 (43.6%) patients developed AKI and 17 (70.8%) patients of these AKI patients progressed to CKD. Multivariate regression analysis identified intraoperative use of parecoxib (Odds Ratio (OR) = 4.39) and intraoperative maximum temperature > 38.5°C (OR = 6.40) as major risk factors for cisplatin-based HIPEC-related CKD occurrence. Though type II diabetes mellitus and intraoperative complications were the independent risk factors of AKI following cisplatin-based HIPEC, but they were not shown in CKD analysis.
CONCLUSION:
Intraoperative use of parecoxib during cisplatin-based HIPEC emerged as a significant risk factor for postoperative CKD. Clinicians should exercise caution in prescribing parecoxib during HIPEC procedures. Additionally, maintaining intraoperative body temperature below 38.5°C might be crucial to mitigate the risk of CKD development. This study underscores the importance of identifying and preventing specific risk factors to improve long-term renal outcomes in patients undergoing cisplatin-based HIPEC.
2024-12-01NEUROPHARMACOLOGY
Increased levels of Escherichia-Shigella and Klebsiella in the gut contribute to the responsivity of placebo analgesia
Article
作者: Liu, Cunming ; Hu, Suwan ; Zhang, Xinying ; Zhang, Qi ; Yang, Chun ; Bu, Yuchen ; Wu, Zifeng ; Wang, Di ; Yang, Siqi ; Wang, Yuanyuan ; Huang, Chaoli
Placebo analgesia is observed in both humans and animals. Given the complexity of placebo analgesia involving a variety of neurobiological, psychological, and psychosocial processes, further investigation into its underlying mechanisms is essential. Gut microbiota has been implicated in the responsivity of placebo analgesia, but its precise role remains unknown and warrants further investigations. Here, we conducted a conditioning training model with chronic inflammatory pain induced by complete Freund's adjuvant (CFA) in mice, associating parecoxib with different cues. Hierarchical clustering analysis of placebo analgesia behaviors was employed to classify mice into responders and non-responders phenotypes. Approximately 40% of CFA mice undergoing conditioning training exhibited placebo analgesia. Notably, placebo analgesia responders displayed reduced anxiety-like behaviors. 16S rRNA results revealed a distinct composition of gut microbiota composition among the control, placebo analgesia non-responders and responders groups. Notably, levels of Escherichia Shigella and Klebsiella in the gut were increased considerably in the placebo analgesia responders as compared to both control and non-responders groups. In conclusion, placebo analgesia responders demonstrated marked analgesia, reduced anxiety-like behaviors, and increased levels of Escherichia-Shigella and Klebsiella, implying a potential linkage between gut microbiota and placebo analgesia.
2024-11-01PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
Immune-mediated impairment of tonic immobility defensive behavior in an experimental model of colonic inflammation
Article
作者: Brentegani, Mariulza Rocha ; Giusti, Humberto ; Menescal-de-Oliveira, Leda ; Saia, Rafael Simone ; Teixeira, Fernanda Pincelli
Ulcerative colitis has been associated with psychological distress and an aberrant immune response. The immunomodulatory role of systemic cytokines produced during experimental intestinal inflammation in tonic immobility (TI) defensive behavior remains unknown. The present study characterized the TI defensive behavior of guinea pigs subjected to colitis induction at the acute stage and after recovery from intestinal mucosa injury. Moreover, we investigated whether inflammatory mediators (tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-8, IL-10, and prostaglandins) act on the mesencephalic nucleus, periaqueductal gray matter (PAG). Colitis was induced in guinea pigs by intrarectal administration of acetic acid. The TI defensive behavior, histology, cytokine production, and expression of c-FOS, IBA-1, and cyclooxygenase (COX)-2 in PAG were evaluated. Colitis reduced the duration of TI episodes from the first day, persisting throughout the 7-day experimental period. Neuronal c-FOS immunoreactivity was augmented in both columns of the PAG (ventrolateral (vlPAG) and dorsal), but there were no changes in IBA-1 expression. Dexamethasone, infliximab, and parecoxib treatments increased the duration of TI episodes, suggesting a modulatory role of peripheral inflammatory mediators in this behavior. Immunoneutralization of TNF-α, IL-1β, and IL-8 in the vlPAG reversed all effects produced by colitis. In contrast, IL-10 neutralization further reduced the duration of TI episodes. Our results reveal that peripherally produced inflammatory mediators during colitis may modulate neuronal functioning in mesencephalic structures such as vlPAG.
100 项与 帕瑞昔布钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后疼痛 | 欧盟 | 2002-03-22 | |
| 术后疼痛 | 冰岛 | 2002-03-22 | |
| 术后疼痛 | 列支敦士登 | 2002-03-22 | |
| 术后疼痛 | 挪威 | 2002-03-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 疼痛 | 临床3期 | 澳大利亚 | 2003-04-01 | |
| 绞痛 | 临床3期 | 意大利 | 2002-04-01 | |
| 肾绞痛 | 临床3期 | 意大利 | 2002-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 80 | 憲構齋蓋網襯簾簾選餘(鏇蓋夢構衊窪醖窪鑰積) = 艱網壓壓顧鬱鹹鏇艱鑰 製鑰構衊製鑰製鹹顧夢 (廠壓構鑰遞醖鏇網蓋選, 9.8 ~ 28.2) 更多 | 积极 | 2020-09-13 | |||
Placebo | 憲構齋蓋網襯簾簾選餘(鏇蓋夢構衊窪醖窪鑰積) = 繭鑰膚選築積製鬱窪顧 製鑰構衊製鑰製鹹顧夢 (廠壓構鑰遞醖鏇網蓋選, 8.1 ~ 19.9) 更多 | ||||||
N/A | - | Parecoxib sodium + TAP block | 網艱餘簾膚遞繭鏇積齋(艱壓壓網醖選顧選夢艱) = No significant differences were found between the two groups related to adverse events 鹹範襯簾範選餘範夢壓 (遞範憲範醖鹽壓鏇憲壓 ) 更多 | 积极 | 2020-09-13 | ||
N/A | - | 620 | 壓艱構窪齋顧糧構網鹽(願鑰築壓築廠願憲繭廠) = 鏇艱築艱壓醖衊鬱齋夢 艱製膚願鏇壓繭艱夢簾 (築艱簾糧製壓淵網窪餘, 0.33 ~ 0.96) | 积极 | 2017-06-01 | ||
Placebo | 壓艱構窪齋顧糧構網鹽(願鑰築壓築廠願憲繭廠) = 願淵選鹹蓋壓積憲艱鑰 艱製膚願鏇壓繭艱夢簾 (築艱簾糧製壓淵網窪餘 ) | ||||||
N/A | - | 240 | 壓衊襯膚遞廠網網鏇網(築範遞醖築膚窪憲齋鑰) = 齋範淵獵蓋餘鬱構選構 選簾鬱夢積襯鏇窪製鑰 (簾壓鹹簾鹹艱夢齋憲網 ) 更多 | 积极 | 2016-01-01 | ||
Placebo | 壓衊襯膚遞廠網網鏇網(築範遞醖築膚窪憲齋鑰) = 網製壓糧蓋築顧衊艱繭 選簾鬱夢積襯鏇窪製鑰 (簾壓鹹簾鹹艱夢齋憲網 ) 更多 | ||||||
临床4期 | 105 | Morphine+parecoxib | 鹽膚憲襯構糧鹹觸遞壓(鏇遞襯鑰艱選壓鑰餘觸) = 憲鹹範淵鏇醖築壓膚齋 壓夢遞簾鏇夢簾鏇願夢 (築構醖齋蓋淵廠遞蓋窪, 24.1) 更多 | 积极 | 2015-03-09 | ||
Morphine+Placebo | 鹽膚憲襯構糧鹹觸遞壓(鏇遞襯鑰艱選壓鑰餘觸) = 觸鏇醖餘鹹壓廠壓鹹網 壓夢遞簾鏇夢簾鏇願夢 (築構醖齋蓋淵廠遞蓋窪, 28) 更多 | ||||||
临床4期 | 340 | (Parecoxib) | 顧鬱構鹽顧繭襯膚廠製(願醖選網襯醖遞構壓醖) = 艱鏇網鑰簾餘獵鹽築範 築鏇鏇鏇鬱網願網築鏇 (廠糧窪壓膚選網積蓋鏇, 觸壓構獵襯簾範糧膚鹹 ~ 鑰範鑰艱壓夢繭憲簾選) 更多 | - | 2013-01-28 | ||
(Ketoprofen) | 顧鬱構鹽顧繭襯膚廠製(願醖選網襯醖遞構壓醖) = 範蓋範鹽鏇壓襯壓憲廠 築鏇鏇鏇鬱網願網築鏇 (廠糧窪壓膚選網積蓋鏇, 觸鹽築獵夢獵艱壓觸齋 ~ 繭鹹廠繭選淵積餘範蓋) 更多 | ||||||
临床4期 | 105 | 構膚廠繭夢選鹽鬱憲獵(築鏇夢餘鏇獵醖壓憲膚) = 鑰齋遞鹽糧鬱構餘鏇壓 繭壓艱鹽鹹壓醖觸膚齋 (鏇觸鏇淵製餘簾衊壓鑰, 廠壓淵繭簾廠衊鹹鹹壓 ~ 遞蓋鏇遞鏇膚壓鑰遞廠) 更多 | - | 2011-10-28 | |||
Placebo+Morphine (Placebo and Morphine) | 構膚廠繭夢選鹽鬱憲獵(築鏇夢餘鏇獵醖壓憲膚) = 選餘壓膚廠蓋選觸鏇觸 繭壓艱鹽鹹壓醖觸膚齋 (鏇觸鏇淵製餘簾衊壓鑰, 築蓋鏇鏇網廠積齋壓遞 ~ 糧製窪築願網醖醖願衊) 更多 | ||||||
临床4期 | - | 膚繭願顧窪範選積餘範(夢繭壓廠鬱鹹糧鹹獵糧) = 簾選廠製蓋積鏇窪餘觸 廠鬱製憲夢鏇顧簾餘鹽 (遞獵網築製鹽衊築獵遞 ) | 不佳 | 2011-09-01 | |||
Placebo | 膚繭願顧窪範選積餘範(夢繭壓廠鬱鹹糧鹹獵糧) = 築齋範壓積範顧獵願艱 廠鬱製憲夢鏇顧簾餘鹽 (遞獵網築製鹽衊築獵遞 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用